C4X-3256
C4X-3256 is an investigational drug developed by C4X Discovery, a biotechnology company focused on drug discovery and development. C4X-3256 is primarily being researched for its potential use in the treatment of addiction, particularly nicotine addiction.
Mechanism of Action[edit | edit source]
C4X-3256 is designed to act as a selective modulator of the nicotinic acetylcholine receptor (nAChR) subtypes. These receptors are involved in the addictive properties of nicotine. By modulating these receptors, C4X-3256 aims to reduce the craving and withdrawal symptoms associated with nicotine addiction, thereby aiding in smoking cessation efforts.
Preclinical and Clinical Development[edit | edit source]
C4X-3256 has undergone extensive preclinical testing to evaluate its efficacy and safety profile. In animal models, the compound has shown promise in reducing nicotine self-administration and withdrawal symptoms. These promising results have led to the initiation of early-phase clinical trials.
Phase I Trials[edit | edit source]
The Phase I clinical trials of C4X-3256 were designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. The trials demonstrated that C4X-3256 was well-tolerated at various dose levels, with no serious adverse effects reported.
Phase II Trials[edit | edit source]
Following successful Phase I trials, C4X-3256 entered Phase II trials to evaluate its efficacy in smokers seeking to quit. These trials are ongoing, with preliminary results indicating a reduction in nicotine cravings and improved abstinence rates compared to placebo.
Potential Impact[edit | edit source]
If successful, C4X-3256 could represent a significant advancement in the treatment of nicotine addiction. Current therapies, such as nicotine replacement therapy and varenicline, have limitations in terms of efficacy and side effects. C4X-3256 offers a novel mechanism of action that could provide an alternative for individuals who have not succeeded with existing treatments.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
